NCT00945035View on ClinicalTrials.gov

Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

December 31, 2002

Study Completion Date

December 31, 2002

Conditions
Pain
Interventions
DRUG

etoricoxib

Single dose etoricoxib 120 mg 20% final market image tablet in one of two treatment periods.

DRUG

Comparator: etoricoxib

Single dose etoricoxib 120 mg 30% unmilled, roller compaction tablet in one of two treatment periods.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00945035 - Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070) | Biotech Hunter | Biotech Hunter